中生制药(01177.HK)附属获「拉尼兰诺」大中华区开发生产商业化独家许可

AAFN2022-09-22

中生制药宣布，附属公司正大天晴药於9月21日与Inventiva S.A.签订正式许可协议，可於中国大陆、香港、澳门、台湾开发、生产并商业化用於治疗非酒精性脂肪性肝炎(NASH)和其他潜在的代谢疾病的「拉尼兰诺」(lanifibranor)。正大天晴将向Inventiva支付1,200万美元的首付款，以及最高不超过4,000万美元的潜在临床及注册里程碑付款，以获得该产品在大中华区独家许可。该...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2269145033?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2022-09-22 16:35","share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","id":"2269145033","market":"us","top_or_hot":-1,"title":"中生制药(01177.HK)附属获「拉尼兰诺」大中华区开发生产商业化独家许可","media":"AAFN","content":"<div>\n<p>中生制药  宣布，附属公司正大天晴药於9月21日与Inventiva S.A.签订正式许可协议，可於中国大陆、香港、澳门、台湾开发、生产并商业化用於治疗非酒精性脂肪性肝炎(NASH)和其他潜在的代谢疾病的「拉尼兰诺」(lanifibranor)。正大天晴将向Inventiva支付1,200万美元的首付款，以及最高不超过4,000万美元的潜在临床及注册里程碑付款，以获得该产品在大中华区独家许可。该...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1215012&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n","source":"aastocks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中生制药(01177.HK)附属获「拉尼兰诺」大中华区开发生产商业化独家许可</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中生制药(01177.HK)附属获「拉尼兰诺」大中华区开发生产商业化独家许可\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-22 16:35 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1215012&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>中生制药  宣布，附属公司正大天晴药於9月21日与Inventiva S.A.签订正式许可协议，可於中国大陆、香港、澳门、台湾开发、生产并商业化用於治疗非酒精性脂肪性肝炎(NASH)和其他潜在的代谢疾病的「拉尼兰诺」(lanifibranor)。正大天晴将向Inventiva支付1,200万美元的首付款，以及最高不超过4,000万美元的潜在临床及注册里程碑付款，以获得该产品在大中华区独家许可。该...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1215012&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1215012&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","article_id":"2269145033","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2269145033","pubTimestamp":1663835721,"columns":[],"sourceInfo":{"source_id":"aastocks","name":"阿思达克财经"},"weMediaInfo":null,"summary":"中生制药  宣布，附属公司正大天晴药於9月21日与Inventiva S.A.签订正式许可协议，可於中国大陆、香港、澳门、台湾开发、生产并商业化用於治疗非酒精性脂肪性肝炎和其他潜在的代谢疾病的「拉尼兰诺」。该产品在大中华区获批上市後，正大天晴将支付额外商业化里程碑付款及基於大中华区销售净额的分层提成。中生制药透露，拉尼兰诺目前正在美国进行III期临床试验，将有望成为第一个获得FDA批准治疗NASH的口服药物。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01177":"中国生物制药","BK1515":"抗疫概念","BK1589":"北水核心资产","BK1191":"制药","BK1521":"挪威政府全球养老基金持仓"},"translate_title":"Zhongsheng Pharmaceutical Co., Ltd. (01177. HK) has obtained the exclusive license for the development, production and commercialization of \"Lanilano\" in Greater China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":0.9,"NASH":1},"content_text":"中生制药  宣布，附属公司正大天晴药於9月21日与Inventiva S.A.签订正式许可协议，可於中国大陆、香港、澳门、台湾开发、生产并商业化用於治疗非酒精性脂肪性肝炎(NASH)和其他潜在的代谢疾病的「拉尼兰诺」(lanifibranor)。正大天晴将向Inventiva支付1,200万美元的首付款，以及最高不超过4,000万美元的潜在临床及注册里程碑付款，以获得该产品在大中华区独家许可。该产品在大中华区获批上市後，正大天晴将支付额外商业化里程碑付款及基於大中华区销售净额的分层提成。公司表示，引进该产品将进一步丰富创新研发管线，完善在NASH领域的布局，为中国肝病患者提供更好的治疗方案。中生制药透露，拉尼兰诺目前正在美国进行III期临床试验，将有望成为第一个获得FDA批准治疗NASH的口服药物。(gc/a)~阿思达克财经新闻网址: www.aastocks.com","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2269145033","isCrawlerRequest":true}